LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

Search

Clearside Biomedical Inc

Gesloten

0.78 -1.27

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.77

Max

0.79

Belangrijke statistieken

By Trading Economics

Inkomsten

-917K

-8.2M

Verkoop

2M

2.3M

EPS

-0.11

Winstmarge

-352.918

Werknemers

32

EBITDA

-102K

-4.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+575% upside

Dividenden

By Dow Jones

Volgende Winsten

11 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-9.7M

59M

Vorige openingsprijs

2.05

Vorige sluitingsprijs

0.78

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

Clearside Biomedical Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 jun 2025, 14:44 UTC

Acquisities, Fusies, Overnames

Justice Department Orders Safran to Sell Assets to Proceed with Buy of Collins Aerospace Business

17 jun 2025, 23:43 UTC

Marktinformatie

Nikkei May Fall Amid Uncertainty Over Israel-Iran Conflict -- Market Talk

17 jun 2025, 23:34 UTC

Marktinformatie

Gold Steady, Underpinned by Ongoing Geopolitical Tensions -- Market Talk

17 jun 2025, 23:22 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 jun 2025, 23:22 UTC

Marktinformatie

Global Energy Roundup: Market Talk

17 jun 2025, 23:22 UTC

Marktinformatie

Meridian Energy Set to Draw Line Under 'Annus Horribilis' -- Market Talk

17 jun 2025, 23:17 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tourism Holdings Likely to Seek Higher Offer -- Market Talk

17 jun 2025, 23:05 UTC

Marktinformatie

Fletcher Building Could Signal Improved Shareholder Returns -- Market Talk

17 jun 2025, 23:05 UTC

Marktinformatie

Global Equities Roundup: Market Talk

17 jun 2025, 22:58 UTC

Marktinformatie

Australian Treasurer Chalmers Expected to Outline Second-Term Reform Agenda -- Market Talk

17 jun 2025, 22:55 UTC

Marktinformatie
Acquisities, Fusies, Overnames

XRG Has a Good Argument for Regulatory Approval of Santos Deal -- Market Talk

17 jun 2025, 22:31 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Lifeway Foods CEO Not Surprised by Takeover Interest -- Market Talk

17 jun 2025, 22:14 UTC

Belangrijke Marktbewegers

Bitdeer Technologies Group Shares Fall on Note Offering

17 jun 2025, 19:49 UTC

Marktinformatie

Natural Gas Slow Down Gains -- Market Talk

17 jun 2025, 19:34 UTC

Marktinformatie

Oil Rises On Israel-Iran Conflict Uncertainty -- Market Talk

17 jun 2025, 19:10 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 jun 2025, 19:10 UTC

Marktinformatie

Dollar Strengthens, Treasury Yields Fall in Risk-Off Trade -- Market Talk

17 jun 2025, 18:41 UTC

Marktinformatie

Slowdown in US Consumer Spending Expected -- Market Talk

17 jun 2025, 18:15 UTC

Marktinformatie

Gold Inches Down as Profit-Taking Seen -- Market Talk

17 jun 2025, 17:44 UTC

Marktinformatie

Analysts Forecast Record-High Ethanol Output -- Market Talk

17 jun 2025, 16:37 UTC

Marktinformatie

A Buy-Canadian Policy Could Support Steel Producers -- Market Talk

17 jun 2025, 16:30 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

17 jun 2025, 16:30 UTC

Marktinformatie

Canada Seen Likely to Drop Digital-Services Tax -- Market Talk

17 jun 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

17 jun 2025, 16:15 UTC

Marktinformatie

Base Metal Prices Mixed on Risk-Off Sentiment -- Market Talk

17 jun 2025, 16:12 UTC

Marktinformatie

Gold Futures Fall as Safe-haven Demand Retreats -- Market Talk

17 jun 2025, 14:54 UTC

Marktinformatie

Oil Rises on Continued Israel-Iran Conflict -- Market Talk

17 jun 2025, 14:47 UTC

Marktinformatie

European Gas Climbs on Middle East Risks, EU Russian Ban Proposal -- Market Talk

17 jun 2025, 14:41 UTC

Marktinformatie

Natural Gas Extends Climb -- Market Talk

17 jun 2025, 14:40 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Clearside Biomedical Inc Prognose

Koersdoel

By TipRanks

575% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.4 USD  575%

Hoogste 8 USD

Laagste 3 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Clearside Biomedical Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technische score

By Trading Central

0.8417 / 0.8939Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Clearside Biomedical Inc

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.